Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment

Kenny, Aidan; McArdle, Hazel; Calero, Miguel; Rábano, Alberto; Madden, Stephen F.; Adamson, Kellie; Forster, Robert J.; Spain, Elaine; Prehn, Jochen H.M.; Henshall, David C.; Medina, Miguel Á.; Jiménez-Mateos, Eva M.; Engel, Tobías

doi:10.2139/ssrn.3429882

Cited by 17 publications

(1 citation statement)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulating data have shown that circulating miRNAs were promising biomarkers to monitor AD pathogenesis [ 46 , 47 , 48 , 49 , 50 , 51 ], and researchers are employing novel analytical platforms in miRNAs biomarker discovery [ 47 , 52 ]. However, there were discrepancies among current studies for reasons including restricted sample sizes, different disease progression stages, sample sources variations (e.g., blood, serum, plasma, CSF, saliva, urine), different human populations, un-uniform methodological processes, etc.…”

Section: Biomarkers Detection In Ad Pathology Studymentioning

confidence: 99%

Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling

Zhao

et al. 2020

Micromachines

View full text Add to dashboard Cite

Early detection and accurate diagnosis of Alzheimer’s disease (AD) is essential for patient care and disease treatment. Microfluidic technology is emerging as an economical and versatile platform in disease detection and diagnosis. It can be conveniently integrated with nanotechnology and/or biological models for biomedical functional and pre-clinical treatment study. These strengths make it advantageous in disease biomarker detection and functional analysis against a wide range of biological backgrounds. This review highlights the recent developments and trends of microfluidic applications in AD research. The first part looks at the principles and methods for AD diagnostic biomarker detection and profiling. The second part discusses how microfluidic chips, especially organ-on-a-chip platforms, could be used as an independent approach and/or integrated with other technologies in AD biomimetic functional analysis.

show abstract

Section: Biomarkers Detection In Ad Pathology Studymentioning

confidence: 99%

Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling

Zhao

et al. 2020

Micromachines

View full text Add to dashboard Cite

show abstract

Exploring advancements in early detection of Alzheimer's disease with molecular assays and animal models

Sethi,

Bhaskar,

Singh

et al. 2024

Ageing Research Reviews

View full text Add to dashboard Cite

Epigenetics of Alzheimer’s Disease

et al. 2021

View full text Add to dashboard Cite

There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer’s disease (AD) or to distinguish it from other dementia-causing neuropathologies. Moreover, to date, only symptomatic treatments exist for this progressive neurodegenerative disorder. In the search for new, more reliable biomarkers and potential therapeutic options, epigenetic modifications have emerged as important players in the pathogenesis of AD. The aim of the article was to provide a brief overview of the current knowledge regarding the role of epigenetics (including mitoepigenetics) in AD, and the possibility of applying these advances for future AD therapy. Extensive research has suggested an important role of DNA methylation and hydroxymethylation, histone posttranslational modifications, and non-coding RNA regulation (with the emphasis on microRNAs) in the course and development of AD. Recent studies also indicated mitochondrial DNA (mtDNA) as an interesting biomarker of AD, since dysfunctions in the mitochondria and lower mtDNA copy number have been associated with AD pathophysiology. The current evidence suggests that epigenetic changes can be successfully detected, not only in the central nervous system, but also in the cerebrospinal fluid and on the periphery, contributing further to their potential as both biomarkers and therapeutic targets in AD.

show abstract

Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment

Cited by 17 publications

References 8 publications

Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling

Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling

Exploring advancements in early detection of Alzheimer's disease with molecular assays and animal models

Epigenetics of Alzheimer’s Disease

Contact Info

Product

Resources

About